Background Heart failure (HF) with reduced ejection fraction represents approximately 50%
of the 600,000 Canadians currently living with HF and over 90,000 new cases diagnosed …

Introduction: Sacubitril-valsartan is a combination drug that contains the neprilysin inhibitor
sacubitril and angiotensin II receptor blocker valsartan. In 2015, the US Food and Drug …

Background Sacubitril/valsartan is an effective treatment for heart failure with reduced
ejection fraction (HFrEF) based on clinical trial data. However, little is known about its use or …

Aims The study aims to explore the real‐world titration patterns of sacubitril/valsartan in a
chronic heart failure (HF) follow‐up management system and the effect on the recovery of …

Abstract Background The PARAGON-HF trial studied the effect of sacubitril/valsartan
(Sac/Val) compared with valsartan (Val) on clinical outcomes in patients with chronic heart …

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the
cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades …

Background: Sacubitril/Valsartan is one of the pillars of heart failure (HF) management. Little
is known about its uses or impact in real-world practice in the Indian population. We …

Background The efficacy and safety of sacubitril/valsartan in patients hospitalized with heart
failure (HF) across the spectrum of left ventricular ejection fraction (EF) has not been …

Aims Sacubitril/valsartan significantly reduced heart failure (HF) hospitalization and
cardiovascular mortality in a randomized controlled trial. However, little is known about real …

Background: The PARALLEL-HF study assessed the efficacy and safety of
sacubitril/valsartan vs. enalapril in Japanese patients with chronic heart failure with reduced …